TSE:PLI - ProMetic Life Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.33 +0.01 (+3.13 %)
(As of 01/16/2019 04:00 PM ET)
Previous CloseC$0.32
Today's RangeC$0.31 - C$0.33
52-Week RangeC$0.25 - C$1.80
Volume942,436 shs
Average Volume1.96 million shs
Market CapitalizationN/A
P/E Ratio-1.75
Dividend YieldN/A
BetaN/A
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+1-450-7810115

Debt

Current Ratio1.52
Quick Ratio0.99

Price-To-Earnings

Sales & Book Value

Annual SalesC$43.37 million
Price / Sales5.46
Cash FlowC$0.03 per share
Price / Cash Flow12.67
Book ValueC$0.05 per share
Price / Book7.33

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees480
OptionableNot Optionable

ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

How were ProMetic Life Sciences' earnings last quarter?

ProMetic Life Sciences Inc. (TSE:PLI) released its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.04) EPS for the quarter. The business earned $12.33 million during the quarter, compared to the consensus estimate of $5.50 million. View ProMetic Life Sciences' Earnings History.

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for ProMetic Life Sciences.

What price target have analysts set for PLI?

3 analysts have issued twelve-month price targets for ProMetic Life Sciences' shares. Their predictions range from C$0.30 to C$2.00. On average, they anticipate ProMetic Life Sciences' share price to reach C$0.92 in the next year. This suggests a possible upside of 178.8% from the stock's current price. View Analyst Price Targets for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 2 sell ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

Media headlines about PLI stock have trended somewhat negative recently, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProMetic Life Sciences earned a news impact score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Prof. Simon Geoffrey Best, Chairman, Pres & CEO (Age 62)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PLI stock can currently be purchased for approximately C$0.33.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://prometic.com/.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  553
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel